Wilson Lin

Wilson Lin

Auto-generated profile, based on publicly available information

Wilson Lin

Department of Medical Physics, University of Wisconsin, 1111 Highland Ave., Madison, WI, 53705, United States

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 July 2021 in Diagnostics
Verified
Journal Article
Open access
PDF file
KBKendall Barrett
Kendall Barrett
HHHailey Houson
Hailey Houson
WLWilson Lin
Wilson Lin
SLSuzane Lapi
Suzane Lapi
Jonathan W EngleJonathan W Engle
Jonathan W Engle
The emerging success of [68Ga/177Lu]Ga/Lu-DOTATATE as a theranostic pair has spurred interest in other isotopes as potential theranostic combinations. Here, we review cobalt-55 and cobalt-58m as a potential theranostic pair. Radionuclidically pure cobalt-55 and cobalt-58m have been produced on small cyclotrons with high molar activity. In vitro, DOTATOC labeled with cobalt has shown greater affinity for SSTR2 than DOTATOC labeled with gallium and yttrium. Similarly, [58mCo]Co-DOTATATE has shown improved cell-killing capabilities as compared to DOTATATE labeled with either indium-111 or lutetium-177. Finally, PET imaging with an isotope such as cobalt-55 allows for image acquisition at much later timepoints than gallium, allowing for an increased degree of biological clearance of non-bound radiotracer. We discuss the accelerator targetry and radiochemistry used to produce cobalt-55,58m, emphasizing the implications of these techniques to downstream radiotracers being developed for imaging and therapy.

6 December 2022 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
HHHailey Houson
Hailey Houson
VTVolkan TEKIN
Volkan TEKIN
WLWilson Lin
Wilson Lin
EAEduardo Aluicio-Sarduy
Eduardo Aluicio-Sarduy
Jonathan W EngleJonathan W Engle
Jonathan W Engle
SLSuzane Lapi
Suzane Lapi
Introduction: Neurotensin receptor 1 (NTSR1) is an emerging target for imaging and therapy of many types of cancer. Nuclear imaging of NTSR1 allows for noninvasive assessment of the receptor levels of NTSR1 on the primary tumor, as well as potential metastases. This work focuses on a the neurotensin peptide analogue NT-20.3 conjugated to the chelator NOTA for radiolabeling for use in noninvasive positron emission tomography (PET). NOTA-NT-20.3 was radiolabeled with gallium-68, copper-64, and cobalt-55 to determine the effect that modification of the radiometal has on imaging and potential therapeutic properties of NOTA-NT-20.3. Methods: In vitro assays investigating cell uptake and subcellular localization of the radiolabeled peptides were performed using human colorectal adenocarcinoma HT29 cells. In vivo PET/CT imaging was used to determine the distribution and clearance of the peptide in mice bearing NTSR1 expressing HT29 tumors. Results: Cell uptake studies showed that the highest uptake was obtained with [55Co] Co-NOTA-NT-20.3 (18.70 ± 1.30%ID/mg), followed by [64Cu] Cu-NOTA-NT-20.3 (15.46 ± 0.91%ID/mg), and lastly [68Ga] Ga-NOTA-NT-20.3 (10.94 ± 0.46%ID/mg) (p < 0.001). Subcellular distribution was similar across the three constructs, with the membranous fraction containing the highest amount of radioactivity. In vivo PET/CT imaging of the three constructs revealed similar distribution and tumor uptake at the 1 h imaging timepoint. Tumor uptake was receptor-specific and blockable by co-injection of non-radiolabeled NOTA-NT-20.3. SUV ratios of tumor to heart at the 24 h imaging timepoint show that [55Co] Co-NOTA-NT-20.3 (20.28 ± 3.04) outperformed [64Cu] Cu-NOTA-NT-20.3 (6.52 ± 1.97). In conclusion, our studies show that enhanced cell uptake and increasing tumor to blood ratios over time displayed the superiority of [55Co] Co-NOTA-NT-20.3 over [68Ga] Ga-NOTA-NT-20.3 and [64Cu] Cu-NOTA-NT-20.3 for the targeting of NTSR1.

13 February 2023 in Nuclear Medicine and Biology
Verified
Journal Article
Closed access
WLWilson Lin
Wilson Lin
EAEduardo Aluicio-Sarduy
Eduardo Aluicio-Sarduy
HHHailey A. Houson
Hailey A. Houson
TBTodd E. Barnhart
Todd E. Barnhart
VTVolkan Tekin
Volkan Tekin
JEJonathan W. Engle
Jonathan W. Engle

27 February 2024 in Bioconjugate Chemistry
Verified
Journal Article
Closed access
WLWilson Lin
Wilson Lin
GCGerman Oscar Fonseca Cabrera
German Oscar Fonseca Cabrera
EAEduardo Aluicio-Sarduy
Eduardo Aluicio-Sarduy
TBTodd E. Barnhart
Todd E. Barnhart
JMJason C. Mixdorf
Jason C. Mixdorf
Jonathan W EngleJonathan W Engle
Jonathan W Engle

29 May 2025 in Cancer Immunology Research
Verified
Journal Article
Closed access
CKCaroline P Kerr
Caroline P Kerr
JSJulia Sheehan-Klenk
Julia Sheehan-Klenk
JGJoseph J. Grudzinski
Joseph J. Grudzinski
DADavid P. Adam
David P. Adam
TNThanh Phuong T. Nguyen
Thanh Phuong T. Nguyen
ZMZachary S. Morris
Zachary S. Morris
Radiopharmaceutical therapies (RPT) activate a type I interferon (IFN1) response in tumor cells. We hypothesized that the timing and amplitude of this response varies by isotope. We compared equal doses delivered by 90Y, 177Lu, and 225Ac in vitro as unbound radionuclides and in vivo when chelated to NM600, a tumor-selective alkylphosphocholine. Response in murine MOC2 head and neck carcinoma and B78 melanoma was evaluated by qPCR and flow cytometry. Therapeutic response to 225Ac-NM600+anti-CTLA4+anti-PD-L1 immune checkpoint inhibition (ICI) was evaluated in wild-type and stimulator of interferon genes knockout (STING KO) B78. The timing and magnitude of the IFN1 response correlated with radionuclide half-life and linear energy transfer. The ratio of CD8+ T cells to regulatory T cells (Treg) increased in tumors 7 days after 90Y- and 177Lu-NM600 and day 21 after 225Ac-NM600. 225Ac-NM600+ICI improved survival in mice with wild-type but not with STING KO tumors, relative to monotherapies. Thus, we have found that the immunomodulatory effects of RPT vary with radioisotope and promote tumor cell STING-dependent enhanced response to ICIs in murine models. These findings have implications for the optimization of RPT–immunotherapy combinations and could guide the relative timing of therapies, the selection of isotope, and patient selection through tumor biomarkers.

25 February 2022 in Nuclear Physics A
Verified
Journal Article
Closed access
WLWilson Lin
Wilson Lin
JWJohn T. Wilkinson
John T. Wilkinson
KBKendall E. Barrett
Kendall E. Barrett
TBTodd E. Barnhart
Todd E. Barnhart
MGMatthew Gott
Matthew Gott
JEJonathan W. Engle
Jonathan W. Engle